Enrique O. S. M.
- Country
- Spain
- Department
- Hematology
Research Overview
- Dose Optimization and Safety Evaluation of ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma
- Efficacy and Safety of Etentamig and Daratumumab Versus Daratumumab and Combination Therapy in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
- AZD0120 Versus Standard Regimens in Relapsed or Refractory Multiple Myeloma: A Phase III Randomised Study
Data & Insights
Has run more than one trial at 85 of 211 partner sites.
Specializations
Multiple Myeloma Treatment Innovation
Specializes in developing novel therapeutic approaches for multiple myeloma, with particular focus on both newly diagnosed and relapsed/refractory cases.
- Combination Therapy Development
- Novel Agent Integration
- Treatment Resistance Management
Investigates innovative drug combinations including belantamab mafodotin, carfilzomib, and daratumumab.
Early-Stage Disease Management
Focuses on optimizing treatment strategies for newly diagnosed multiple myeloma patients, particularly evaluating responses in specific age groups and fitness levels.
- Age-Specific Treatment Protocols
- Transplant-Eligible Patient Care
- Response Assessment Methods
Specializes in immunophenotypic response evaluation and minimal residual disease assessment.
Advanced Disease Treatment
Expertise in managing relapsed/refractory multiple myeloma through innovative therapeutic combinations and novel agents.
- Novel Drug Development
- Targeted Therapy Approaches
- Treatment Sequencing Strategies
Investigates emerging treatments including elranatamab and selinexor-based combinations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.